Dual block versus single agent trastuzumab plus chemotherapy as neoadjuvant treatment of HER2-positive breast cancer: a meta-analysis of randomized trials

被引：0
|
作者：
Clavarezza, M. [1 ]
Puntoni, M. [2 ]
Gennari, A. [1 ]
Paleari, L. [1 ]
Provinciali, N. [1 ]
D'Amico, M. [1 ]
Decensi, A. [1 ]
机构：
[1] Osped Galliera, Oncol Unit, Genoa, Italy
[2] Osped Galliera, Clin Trial & Biostat Unit, Sci Direct, Genoa, Italy
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw364.60
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
204P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer (BC).
    Guarneri, Valentina
    Dieci, Maria Vittoria
    Bisagni, Giancarlo
    Generali, Daniele Giulio
    Cagossi, Katia
    Sarti, Samanta
    Frassoldati, Antonio
    Gianni, Lorenzo
    Cavanna, Luigi
    Pinotti, Graziella
    Musolino, Antonino
    Piacentini, Federico
    Michelotti, Andrea
    Cinieri, Saverio
    Griguolo, Gaia
    Miglietta, Federica
    De Salvo, Gian Luca
    Conte, Pier Franco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] Trastuzumab plus Paclitaxel in HER2-positive Breast Cancer
    不详
    [J]. GYNAKOLOGE, 2016, 49 (08): : 558 - 558
  • [33] Early and late outcomes of bevacizumab plus chemotherapy versus chemotherapy alone as a neoadjuvant treatment in HER2-negative nonmetastatic breast cancer: a meta-analysis of randomized controlled trials
    Wei, Jinli
    Luo, Yulin
    Fu, Deyuan
    [J]. ONCOTARGETS AND THERAPY, 2018, 11 : 9049 - 9059
  • [34] Prognostic Factors in HER2-Positive Primary Breast Cancer Patients Treated Using Neoadjuvant Chemotherapy Plus Trastuzumab
    Fujita, Noriko
    Enomoto, Yukie
    Inakami, Keiko
    Yanagisawa, Tetsu
    Iguchi, Chikage
    Aono, Toyokazu
    Nomura, Takashi
    Yamamoto, Hitoshi
    Kasugai, Tsutomu
    Shiba, Eiichi
    [J]. ONCOLOGY, 2020, 98 (01) : 35 - 41
  • [35] Neoadjuvant Dual HER2-Targeted Therapy With Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients With Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials
    Hicks, Mellissa
    Macrae, Erin R.
    Abdel-Rasoul, Mahmoud
    Layman, Rachel
    Friedman, Susan
    Querry, Jenny
    Lustberg, Maryam
    Ramaswamy, Bhuvaneswari
    Mrozek, Ewa
    Shapiro, Charles
    Wesolowski, Robert
    [J]. ONCOLOGIST, 2015, 20 (04): : 337 - 343
  • [36] Retrospective single-center outcome analysis of neoadjuvant and palliative treatment with dual trastuzumab and pertuzumab in HER2-positive breast cancer.
    Marhold, Maximilian
    Ionce, Lea Roxana
    Christ, Alexandra
    Aretin, Marie-Bernadette
    Sagaster, Verena
    Exner, Ruth
    Wimmer, Kerstin
    Devyatko, Yelena
    Fitzal, Florian
    Steger, Guenther G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
    Nakatsukasa, Katsuhiko
    Taguchi, Tetsuya
    Sugimoto, Riho
    Sakaguchi, Kouichi
    Kotani, Tatsuya
    Hukuda, Kenichirou
    Kawakami, Sadao
    Hujiwara, Ikuya
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] The updated network meta-analysis of neoadjuvant therapy for HER2-positive breast cancer
    Nakashoji, Ayako
    Hayashida, Tetsu
    Yokoe, Takamichi
    Maeda, Hinako
    Toyota, Tomoka
    Kikuchi, Masayuki
    Watanuki, Rurina
    Nagayama, Aiko
    Seki, Tomoko
    Takahashi, Maiko
    Abe, Takayuki
    Kitagawa, Yuko
    [J]. CANCER TREATMENT REVIEWS, 2018, 62 : 9 - 17
  • [39] Trastuzumab combined chemotherapy for the treatment of HER2-positive advanced gastric cancer: A systematic review and meta-analysis of randomized controlled trial
    Xue, Chuan
    Xu, Yong-Hong
    [J]. MEDICINE, 2022, 101 (34) : E29992
  • [40] Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis
    Liu, Tong
    Liu, Duo
    Jin, Yao
    Dong, Mei
    [J]. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2022, 44 (06) : 809 - 815
12345